A clinical study to evaluate the efficacy of Amalaki Churna in Pandu Vyadhi with special reference to Iron Deficiency Anaemia
Department of Kayachikitsa, M.A.M.’s Sumatibhai Shah Ayurved Mahavidyala, Malwadi, Hadapasar, Pune - 411028, Maharashtra State, India.
Research Article
World Journal of Advanced Research and Reviews, 2022, 16(03), 1108-1111
Article DOI: 10.30574/wjarr.2022.16.3.1484
Publication history:
Received on 19 November 2022; revised on 26 December 2022; accepted on 29 December 2022
Abstract:
Iron Deficiency Anaemia (IDA) is the most common type of Anaemia overall, and is caused when the dietary intake or absorption of Iron is insufficient. According to National family health survey, India report Anaemia affects an estimated 50% of the Indian population.[1] Rasayana Chikitsa is very beneficial to the patient of Pandu (IDA). In these diseases, the Saarta(essence) of all dhatus is lost hence the dhatus becomes Nissari.e., loss of qualitative physiological excellence, which ultimately results in Oja-Kshaya.[2] Here 30 patients were selected randomly in the study and given Amalaki Churna in 3 gms/day. At the end of 30 days symptomatic improvement and increase in Hb% in Group were noticed. No significant therapy is there for chronic Anaemias in Modern science, which are often due to metabolic defect, so an attempt has been made to evaluate the efficacy of Amalaki Churna on Iron Deficiency Anaemia. It is reported that this drug has useful role in preventing Iron deficiency Anaemia due to metabolic defect.
Keywords:
Panduroga; Iron Deficiency Anaemia; Anaemia; Rasayana; Amalaki
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0